nodes	percent_of_prediction	percent_of_DWPC	metapath
Glyburide—ABCC1—Vemurafenib—skin cancer	0.0779	0.1	CbGbCtD
Glyburide—ABCG2—Vismodegib—skin cancer	0.066	0.0846	CbGbCtD
Glyburide—ABCC3—Fluorouracil—skin cancer	0.057	0.0732	CbGbCtD
Glyburide—ABCG2—Vemurafenib—skin cancer	0.0521	0.0669	CbGbCtD
Glyburide—ABCC1—Dactinomycin—skin cancer	0.0518	0.0664	CbGbCtD
Glyburide—ALB—Vismodegib—skin cancer	0.0455	0.0583	CbGbCtD
Glyburide—SLC22A7—Fluorouracil—skin cancer	0.0446	0.0572	CbGbCtD
Glyburide—ALB—Vemurafenib—skin cancer	0.0359	0.0461	CbGbCtD
Glyburide—ABCG2—Dactinomycin—skin cancer	0.0347	0.0445	CbGbCtD
Glyburide—SLC22A7—Docetaxel—skin cancer	0.0341	0.0437	CbGbCtD
Glyburide—CYP2C19—Vismodegib—skin cancer	0.0295	0.0378	CbGbCtD
Glyburide—ABCC1—Docetaxel—skin cancer	0.0267	0.0343	CbGbCtD
Glyburide—CYP2C9—Vismodegib—skin cancer	0.0245	0.0314	CbGbCtD
Glyburide—ABCB1—Vismodegib—skin cancer	0.0238	0.0305	CbGbCtD
Glyburide—ABCG2—Fluorouracil—skin cancer	0.0234	0.0301	CbGbCtD
Glyburide—CFTR—sweat gland—skin cancer	0.0228	0.266	CbGeAlD
Glyburide—CYP3A4—Imiquimod—skin cancer	0.0206	0.0264	CbGbCtD
Glyburide—CYP3A4—Temozolomide—skin cancer	0.0206	0.0264	CbGbCtD
Glyburide—ABCC2—Docetaxel—skin cancer	0.0198	0.0254	CbGbCtD
Glyburide—ABCG2—Docetaxel—skin cancer	0.0179	0.023	CbGbCtD
Glyburide—ALB—Fluorouracil—skin cancer	0.0162	0.0207	CbGbCtD
Glyburide—CYP3A4—Vismodegib—skin cancer	0.0143	0.0183	CbGbCtD
Glyburide—CFTR—nose—skin cancer	0.0131	0.153	CbGeAlD
Glyburide—ABCB1—Dactinomycin—skin cancer	0.0125	0.016	CbGbCtD
Glyburide—CYP3A4—Vemurafenib—skin cancer	0.0113	0.0145	CbGbCtD
Glyburide—CYP2C9—Fluorouracil—skin cancer	0.00871	0.0112	CbGbCtD
Glyburide—ABCB1—Docetaxel—skin cancer	0.00645	0.00828	CbGbCtD
Glyburide—KCNJ1—appendage—skin cancer	0.00588	0.0687	CbGeAlD
Glyburide—ABCC8—penis—skin cancer	0.00507	0.0593	CbGeAlD
Glyburide—CYP3A4—Docetaxel—skin cancer	0.00387	0.00496	CbGbCtD
Glyburide—ABCA1—blood vessel—skin cancer	0.00312	0.0364	CbGeAlD
Glyburide—KCNJ5—lymphoid tissue—skin cancer	0.00227	0.0266	CbGeAlD
Glyburide—KCNJ5—head—skin cancer	0.00183	0.0214	CbGeAlD
Glyburide—CPT1A—connective tissue—skin cancer	0.00171	0.02	CbGeAlD
Glyburide—ABCA1—connective tissue—skin cancer	0.0016	0.0187	CbGeAlD
Glyburide—ABCA1—skin of body—skin cancer	0.00144	0.0168	CbGeAlD
Glyburide—CFTR—epithelium—skin cancer	0.00143	0.0167	CbGeAlD
Glyburide—CPT1A—female reproductive system—skin cancer	0.00121	0.0141	CbGeAlD
Glyburide—ABCA1—lymphoid tissue—skin cancer	0.00117	0.0136	CbGeAlD
Glyburide—ABCC1—hair follicle—skin cancer	0.00115	0.0135	CbGeAlD
Glyburide—ABCA1—female reproductive system—skin cancer	0.00113	0.0132	CbGeAlD
Glyburide—CFTR—female reproductive system—skin cancer	0.00106	0.0124	CbGeAlD
Glyburide—CPT1A—head—skin cancer	0.00101	0.0118	CbGeAlD
Glyburide—KCNJ1—head—skin cancer	0.000989	0.0116	CbGeAlD
Glyburide—ABCC9—lymph node—skin cancer	0.000972	0.0114	CbGeAlD
Glyburide—ABCA1—head—skin cancer	0.000941	0.011	CbGeAlD
Glyburide—CFTR—head—skin cancer	0.000889	0.0104	CbGeAlD
Glyburide—Hyperbilirubinaemia—Temozolomide—skin cancer	0.000882	0.00707	CcSEcCtD
Glyburide—Eruption—Docetaxel—skin cancer	0.000867	0.00695	CcSEcCtD
Glyburide—SLC15A1—epithelium—skin cancer	0.000851	0.00994	CbGeAlD
Glyburide—Aplastic anaemia—Dactinomycin—skin cancer	0.000833	0.00668	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Vismodegib—skin cancer	0.000826	0.00662	CcSEcCtD
Glyburide—Sweating increased—Imiquimod—skin cancer	0.000818	0.00656	CcSEcCtD
Glyburide—Dyspepsia—Vismodegib—skin cancer	0.000798	0.0064	CcSEcCtD
Glyburide—Pancytopenia—Imiquimod—skin cancer	0.000797	0.00639	CcSEcCtD
Glyburide—Decreased appetite—Vismodegib—skin cancer	0.000788	0.00632	CcSEcCtD
Glyburide—Gastrointestinal disorder—Vismodegib—skin cancer	0.000782	0.00627	CcSEcCtD
Glyburide—ABCC1—nipple—skin cancer	0.000782	0.00913	CbGeAlD
Glyburide—Heartburn—Docetaxel—skin cancer	0.000775	0.00621	CcSEcCtD
Glyburide—Photosensitivity reaction—Imiquimod—skin cancer	0.000767	0.00615	CcSEcCtD
Glyburide—Aplastic anaemia—Temozolomide—skin cancer	0.000753	0.00604	CcSEcCtD
Glyburide—KCNJ11—lymphoid tissue—skin cancer	0.000745	0.0087	CbGeAlD
Glyburide—Gastrointestinal pain—Vismodegib—skin cancer	0.000741	0.00594	CcSEcCtD
Glyburide—SLC15A1—mammalian vulva—skin cancer	0.000738	0.00863	CbGeAlD
Glyburide—Eye disorder—Vemurafenib—skin cancer	0.000737	0.00591	CcSEcCtD
Glyburide—KCNJ11—female reproductive system—skin cancer	0.000718	0.00839	CbGeAlD
Glyburide—Abdominal pain—Vismodegib—skin cancer	0.000716	0.00574	CcSEcCtD
Glyburide—Hepatic failure—Dactinomycin—skin cancer	0.000716	0.00574	CcSEcCtD
Glyburide—Arthritis—Bleomycin—skin cancer	0.00071	0.00569	CcSEcCtD
Glyburide—CPT1A—lymph node—skin cancer	0.000707	0.00826	CbGeAlD
Glyburide—Alopecia—Vemurafenib—skin cancer	0.000696	0.00558	CcSEcCtD
Glyburide—Erythema—Vemurafenib—skin cancer	0.000686	0.0055	CcSEcCtD
Glyburide—Malnutrition—Vemurafenib—skin cancer	0.000686	0.0055	CcSEcCtD
Glyburide—CPT1A—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000677	0.0658	CbGpPWpGaD
Glyburide—ABCA1—lymph node—skin cancer	0.000659	0.0077	CbGeAlD
Glyburide—Deafness—Temozolomide—skin cancer	0.000651	0.00522	CcSEcCtD
Glyburide—Vascular purpura—Temozolomide—skin cancer	0.000651	0.00522	CcSEcCtD
Glyburide—Asthenia—Vismodegib—skin cancer	0.00065	0.00521	CcSEcCtD
Glyburide—Hepatic failure—Temozolomide—skin cancer	0.000648	0.00519	CcSEcCtD
Glyburide—Visual impairment—Imiquimod—skin cancer	0.000648	0.00519	CcSEcCtD
Glyburide—Pruritus—Vismodegib—skin cancer	0.000641	0.00514	CcSEcCtD
Glyburide—Eye disorder—Imiquimod—skin cancer	0.000628	0.00504	CcSEcCtD
Glyburide—Diarrhoea—Vismodegib—skin cancer	0.00062	0.00497	CcSEcCtD
Glyburide—Purpura—Temozolomide—skin cancer	0.000604	0.00484	CcSEcCtD
Glyburide—KCNJ11—head—skin cancer	0.0006	0.00701	CbGeAlD
Glyburide—Alopecia—Imiquimod—skin cancer	0.000594	0.00476	CcSEcCtD
Glyburide—Hyperbilirubinaemia—Docetaxel—skin cancer	0.000587	0.0047	CcSEcCtD
Glyburide—Erythema—Imiquimod—skin cancer	0.000585	0.00469	CcSEcCtD
Glyburide—Malnutrition—Imiquimod—skin cancer	0.000585	0.00469	CcSEcCtD
Glyburide—Arthralgia—Vemurafenib—skin cancer	0.000584	0.00468	CcSEcCtD
Glyburide—Myalgia—Vemurafenib—skin cancer	0.000584	0.00468	CcSEcCtD
Glyburide—Diplopia—Temozolomide—skin cancer	0.000582	0.00467	CcSEcCtD
Glyburide—Vomiting—Vismodegib—skin cancer	0.000576	0.00462	CcSEcCtD
Glyburide—Rash—Vismodegib—skin cancer	0.000571	0.00458	CcSEcCtD
Glyburide—Dermatitis—Vismodegib—skin cancer	0.000571	0.00458	CcSEcCtD
Glyburide—Pancytopenia—Bleomycin—skin cancer	0.000567	0.00454	CcSEcCtD
Glyburide—Dermatitis bullous—Fluorouracil—skin cancer	0.000561	0.0045	CcSEcCtD
Glyburide—ABCC3—female reproductive system—skin cancer	0.000555	0.00649	CbGeAlD
Glyburide—ABCC8—head—skin cancer	0.000553	0.00646	CbGeAlD
Glyburide—Nervous system disorder—Vemurafenib—skin cancer	0.000549	0.0044	CcSEcCtD
Glyburide—Nausea—Vismodegib—skin cancer	0.000538	0.00432	CcSEcCtD
Glyburide—Angioedema—Imiquimod—skin cancer	0.000535	0.00429	CcSEcCtD
Glyburide—Pancytopenia—Dactinomycin—skin cancer	0.000528	0.00424	CcSEcCtD
Glyburide—Hypotension—Vemurafenib—skin cancer	0.000523	0.00419	CcSEcCtD
Glyburide—SLCO2B1—female reproductive system—skin cancer	0.000518	0.00605	CbGeAlD
Glyburide—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00051	0.00409	CcSEcCtD
Glyburide—Convulsion—Imiquimod—skin cancer	0.000507	0.00406	CcSEcCtD
Glyburide—Abdominal distension—Temozolomide—skin cancer	0.000507	0.00406	CcSEcCtD
Glyburide—Myalgia—Imiquimod—skin cancer	0.000498	0.00399	CcSEcCtD
Glyburide—Arthralgia—Imiquimod—skin cancer	0.000498	0.00399	CcSEcCtD
Glyburide—Sweating increased—Temozolomide—skin cancer	0.00049	0.00393	CcSEcCtD
Glyburide—Decreased appetite—Vemurafenib—skin cancer	0.000487	0.0039	CcSEcCtD
Glyburide—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000483	0.00388	CcSEcCtD
Glyburide—Pancytopenia—Temozolomide—skin cancer	0.000478	0.00383	CcSEcCtD
Glyburide—Oedema—Imiquimod—skin cancer	0.000478	0.00383	CcSEcCtD
Glyburide—Shock—Imiquimod—skin cancer	0.00047	0.00377	CcSEcCtD
Glyburide—Nervous system disorder—Imiquimod—skin cancer	0.000468	0.00375	CcSEcCtD
Glyburide—ABCC3—head—skin cancer	0.000464	0.00542	CbGeAlD
Glyburide—Agranulocytosis—Dactinomycin—skin cancer	0.000463	0.00371	CcSEcCtD
Glyburide—Hyperhidrosis—Imiquimod—skin cancer	0.000462	0.0037	CcSEcCtD
Glyburide—Photosensitivity reaction—Temozolomide—skin cancer	0.000459	0.00368	CcSEcCtD
Glyburide—Eosinophilia—Fluorouracil—skin cancer	0.000459	0.00368	CcSEcCtD
Glyburide—ABCC1—mammalian vulva—skin cancer	0.000457	0.00533	CbGeAlD
Glyburide—Anorexia—Imiquimod—skin cancer	0.000455	0.00365	CcSEcCtD
Glyburide—Hepatitis—Dactinomycin—skin cancer	0.000445	0.00357	CcSEcCtD
Glyburide—SLC22A7—Fluoropyrimidine Activity—XRCC3—skin cancer	0.000444	0.0432	CbGpPWpGaD
Glyburide—ABCC2—female reproductive system—skin cancer	0.000444	0.00518	CbGeAlD
Glyburide—ABCB1—blood vessel—skin cancer	0.000441	0.00516	CbGeAlD
Glyburide—Pancytopenia—Fluorouracil—skin cancer	0.00044	0.00353	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000435	0.00349	CcSEcCtD
Glyburide—Deafness—Docetaxel—skin cancer	0.000433	0.00347	CcSEcCtD
Glyburide—SLCO2B1—head—skin cancer	0.000433	0.00505	CbGeAlD
Glyburide—Hepatic failure—Docetaxel—skin cancer	0.000431	0.00345	CcSEcCtD
Glyburide—Paraesthesia—Imiquimod—skin cancer	0.000429	0.00344	CcSEcCtD
Glyburide—Dyspnoea—Imiquimod—skin cancer	0.000426	0.00341	CcSEcCtD
Glyburide—Photosensitivity reaction—Fluorouracil—skin cancer	0.000423	0.00339	CcSEcCtD
Glyburide—Alopecia—Bleomycin—skin cancer	0.000422	0.00338	CcSEcCtD
Glyburide—Dyspepsia—Imiquimod—skin cancer	0.00042	0.00337	CcSEcCtD
Glyburide—KCNJ11—lymph node—skin cancer	0.00042	0.00491	CbGeAlD
Glyburide—ABCC8—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000418	0.0406	CbGpPWpGaD
Glyburide—Erythema—Bleomycin—skin cancer	0.000416	0.00333	CcSEcCtD
Glyburide—Decreased appetite—Imiquimod—skin cancer	0.000415	0.00333	CcSEcCtD
Glyburide—Hypersensitivity—Vemurafenib—skin cancer	0.000413	0.00331	CcSEcCtD
Glyburide—Gastrointestinal disorder—Imiquimod—skin cancer	0.000412	0.00331	CcSEcCtD
Glyburide—Visual disturbance—Docetaxel—skin cancer	0.000409	0.00328	CcSEcCtD
Glyburide—Renal impairment—Docetaxel—skin cancer	0.000407	0.00326	CcSEcCtD
Glyburide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000405	0.0394	CbGpPWpGaD
Glyburide—Dermatitis bullous—Docetaxel—skin cancer	0.000405	0.00325	CcSEcCtD
Glyburide—Hepatitis—Temozolomide—skin cancer	0.000403	0.00323	CcSEcCtD
Glyburide—Asthenia—Vemurafenib—skin cancer	0.000402	0.00322	CcSEcCtD
Glyburide—SLCO1A2—head—skin cancer	0.000398	0.00465	CbGeAlD
Glyburide—Pruritus—Vemurafenib—skin cancer	0.000396	0.00318	CcSEcCtD
Glyburide—SLC15A2—female reproductive system—skin cancer	0.000395	0.00462	CbGeAlD
Glyburide—Alopecia—Dactinomycin—skin cancer	0.000394	0.00316	CcSEcCtD
Glyburide—Feeling abnormal—Imiquimod—skin cancer	0.000394	0.00315	CcSEcCtD
Glyburide—Gastrointestinal pain—Imiquimod—skin cancer	0.00039	0.00313	CcSEcCtD
Glyburide—Hyponatraemia—Docetaxel—skin cancer	0.000389	0.00312	CcSEcCtD
Glyburide—Visual impairment—Temozolomide—skin cancer	0.000388	0.00311	CcSEcCtD
Glyburide—Erythema—Dactinomycin—skin cancer	0.000388	0.00311	CcSEcCtD
Glyburide—Agranulocytosis—Fluorouracil—skin cancer	0.000386	0.00309	CcSEcCtD
Glyburide—Anaemia—Bleomycin—skin cancer	0.000384	0.00308	CcSEcCtD
Glyburide—Diarrhoea—Vemurafenib—skin cancer	0.000383	0.00307	CcSEcCtD
Glyburide—ABCC3—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00038	0.037	CbGpPWpGaD
Glyburide—Urticaria—Imiquimod—skin cancer	0.000379	0.00304	CcSEcCtD
Glyburide—ABCG2—mammalian vulva—skin cancer	0.000378	0.00442	CbGeAlD
Glyburide—Abdominal pain—Imiquimod—skin cancer	0.000378	0.00303	CcSEcCtD
Glyburide—Eye disorder—Temozolomide—skin cancer	0.000376	0.00302	CcSEcCtD
Glyburide—Leukopenia—Bleomycin—skin cancer	0.000372	0.00298	CcSEcCtD
Glyburide—Anaemia—Dactinomycin—skin cancer	0.000358	0.00287	CcSEcCtD
Glyburide—Vomiting—Vemurafenib—skin cancer	0.000356	0.00285	CcSEcCtD
Glyburide—Alopecia—Temozolomide—skin cancer	0.000356	0.00285	CcSEcCtD
Glyburide—Myalgia—Bleomycin—skin cancer	0.000354	0.00284	CcSEcCtD
Glyburide—Rash—Vemurafenib—skin cancer	0.000353	0.00283	CcSEcCtD
Glyburide—Dermatitis—Vemurafenib—skin cancer	0.000353	0.00283	CcSEcCtD
Glyburide—Hypersensitivity—Imiquimod—skin cancer	0.000352	0.00282	CcSEcCtD
Glyburide—Headache—Vemurafenib—skin cancer	0.000351	0.00281	CcSEcCtD
Glyburide—Erythema—Temozolomide—skin cancer	0.000351	0.00281	CcSEcCtD
Glyburide—Malnutrition—Temozolomide—skin cancer	0.000351	0.00281	CcSEcCtD
Glyburide—Leukopenia—Dactinomycin—skin cancer	0.000347	0.00278	CcSEcCtD
Glyburide—CPT1A—PPARA activates gene expression—PLIN2—skin cancer	0.000343	0.0333	CbGpPWpGaD
Glyburide—ABCA1—PPARA activates gene expression—PLIN2—skin cancer	0.000343	0.0333	CbGpPWpGaD
Glyburide—Asthenia—Imiquimod—skin cancer	0.000343	0.00275	CcSEcCtD
Glyburide—Confusional state—Bleomycin—skin cancer	0.000342	0.00274	CcSEcCtD
Glyburide—Oedema—Bleomycin—skin cancer	0.000339	0.00272	CcSEcCtD
Glyburide—Pruritus—Imiquimod—skin cancer	0.000338	0.00271	CcSEcCtD
Glyburide—CPT1A—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PLIN2—skin cancer	0.000336	0.0326	CbGpPWpGaD
Glyburide—ABCA1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PLIN2—skin cancer	0.000336	0.0326	CbGpPWpGaD
Glyburide—Nausea—Vemurafenib—skin cancer	0.000333	0.00267	CcSEcCtD
Glyburide—Thrombocytopenia—Bleomycin—skin cancer	0.000332	0.00266	CcSEcCtD
Glyburide—Vision blurred—Temozolomide—skin cancer	0.00033	0.00265	CcSEcCtD
Glyburide—SLC15A2—head—skin cancer	0.00033	0.00386	CbGeAlD
Glyburide—Myalgia—Dactinomycin—skin cancer	0.00033	0.00265	CcSEcCtD
Glyburide—Tremor—Temozolomide—skin cancer	0.000329	0.00263	CcSEcCtD
Glyburide—Alopecia—Fluorouracil—skin cancer	0.000328	0.00263	CcSEcCtD
Glyburide—Diarrhoea—Imiquimod—skin cancer	0.000327	0.00262	CcSEcCtD
Glyburide—ABCC3—lymph node—skin cancer	0.000325	0.0038	CbGeAlD
Glyburide—Anaemia—Temozolomide—skin cancer	0.000324	0.0026	CcSEcCtD
Glyburide—Anorexia—Bleomycin—skin cancer	0.000323	0.00259	CcSEcCtD
Glyburide—Erythema—Fluorouracil—skin cancer	0.000323	0.00259	CcSEcCtD
Glyburide—Angioedema—Temozolomide—skin cancer	0.00032	0.00257	CcSEcCtD
Glyburide—Pancytopenia—Docetaxel—skin cancer	0.000318	0.00255	CcSEcCtD
Glyburide—Hypotension—Bleomycin—skin cancer	0.000317	0.00254	CcSEcCtD
Glyburide—Oedema—Dactinomycin—skin cancer	0.000316	0.00254	CcSEcCtD
Glyburide—Leukopenia—Temozolomide—skin cancer	0.000314	0.00252	CcSEcCtD
Glyburide—Thrombocytopenia—Dactinomycin—skin cancer	0.00031	0.00248	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000309	0.00248	CcSEcCtD
Glyburide—Paraesthesia—Bleomycin—skin cancer	0.000305	0.00244	CcSEcCtD
Glyburide—Vision blurred—Fluorouracil—skin cancer	0.000304	0.00244	CcSEcCtD
Glyburide—Convulsion—Temozolomide—skin cancer	0.000304	0.00244	CcSEcCtD
Glyburide—Vomiting—Imiquimod—skin cancer	0.000304	0.00243	CcSEcCtD
Glyburide—SLCO2B1—lymph node—skin cancer	0.000303	0.00354	CbGeAlD
Glyburide—Dyspnoea—Bleomycin—skin cancer	0.000302	0.00242	CcSEcCtD
Glyburide—Anorexia—Dactinomycin—skin cancer	0.000302	0.00242	CcSEcCtD
Glyburide—Rash—Imiquimod—skin cancer	0.000301	0.00241	CcSEcCtD
Glyburide—Dermatitis—Imiquimod—skin cancer	0.000301	0.00241	CcSEcCtD
Glyburide—Headache—Imiquimod—skin cancer	0.000299	0.0024	CcSEcCtD
Glyburide—Anaemia—Fluorouracil—skin cancer	0.000299	0.00239	CcSEcCtD
Glyburide—Myalgia—Temozolomide—skin cancer	0.000299	0.00239	CcSEcCtD
Glyburide—Arthralgia—Temozolomide—skin cancer	0.000299	0.00239	CcSEcCtD
Glyburide—CYP2C9—female reproductive system—skin cancer	0.000296	0.00345	CbGeAlD
Glyburide—Decreased appetite—Bleomycin—skin cancer	0.000295	0.00236	CcSEcCtD
Glyburide—Jaundice—Docetaxel—skin cancer	0.000291	0.00233	CcSEcCtD
Glyburide—CPT1A—PPAR Alpha Pathway—CDK4—skin cancer	0.00029	0.0282	CbGpPWpGaD
Glyburide—Leukopenia—Fluorouracil—skin cancer	0.000289	0.00232	CcSEcCtD
Glyburide—Confusional state—Temozolomide—skin cancer	0.000289	0.00231	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000288	0.00231	CcSEcCtD
Glyburide—Oedema—Temozolomide—skin cancer	0.000286	0.00229	CcSEcCtD
Glyburide—Nausea—Imiquimod—skin cancer	0.000284	0.00227	CcSEcCtD
Glyburide—Nervous system disorder—Temozolomide—skin cancer	0.000281	0.00225	CcSEcCtD
Glyburide—Thrombocytopenia—Temozolomide—skin cancer	0.00028	0.00225	CcSEcCtD
Glyburide—Convulsion—Fluorouracil—skin cancer	0.00028	0.00224	CcSEcCtD
Glyburide—Feeling abnormal—Bleomycin—skin cancer	0.00028	0.00224	CcSEcCtD
Glyburide—Agranulocytosis—Docetaxel—skin cancer	0.000278	0.00223	CcSEcCtD
Glyburide—ALB—lymph node—skin cancer	0.000277	0.00324	CbGeAlD
Glyburide—Hyperhidrosis—Temozolomide—skin cancer	0.000277	0.00222	CcSEcCtD
Glyburide—Myalgia—Fluorouracil—skin cancer	0.000275	0.00221	CcSEcCtD
Glyburide—Decreased appetite—Dactinomycin—skin cancer	0.000275	0.00221	CcSEcCtD
Glyburide—Anorexia—Temozolomide—skin cancer	0.000273	0.00219	CcSEcCtD
Glyburide—Urticaria—Bleomycin—skin cancer	0.00027	0.00216	CcSEcCtD
Glyburide—Hepatitis—Docetaxel—skin cancer	0.000268	0.00215	CcSEcCtD
Glyburide—Confusional state—Fluorouracil—skin cancer	0.000266	0.00213	CcSEcCtD
Glyburide—Oedema—Fluorouracil—skin cancer	0.000264	0.00211	CcSEcCtD
Glyburide—ABCG2—Fluoropyrimidine Activity—XRCC3—skin cancer	0.000262	0.0255	CbGpPWpGaD
Glyburide—Feeling abnormal—Dactinomycin—skin cancer	0.000261	0.00209	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000261	0.00209	CcSEcCtD
Glyburide—ABCC2—lymph node—skin cancer	0.00026	0.00303	CbGeAlD
Glyburide—Gastrointestinal pain—Dactinomycin—skin cancer	0.000259	0.00207	CcSEcCtD
Glyburide—Nervous system disorder—Fluorouracil—skin cancer	0.000259	0.00207	CcSEcCtD
Glyburide—Thrombocytopenia—Fluorouracil—skin cancer	0.000258	0.00207	CcSEcCtD
Glyburide—Visual impairment—Docetaxel—skin cancer	0.000258	0.00207	CcSEcCtD
Glyburide—Paraesthesia—Temozolomide—skin cancer	0.000257	0.00206	CcSEcCtD
Glyburide—Dyspnoea—Temozolomide—skin cancer	0.000255	0.00205	CcSEcCtD
Glyburide—Dyspepsia—Temozolomide—skin cancer	0.000252	0.00202	CcSEcCtD
Glyburide—Anorexia—Fluorouracil—skin cancer	0.000251	0.00202	CcSEcCtD
Glyburide—Eye disorder—Docetaxel—skin cancer	0.00025	0.00201	CcSEcCtD
Glyburide—Abdominal pain—Dactinomycin—skin cancer	0.00025	0.00201	CcSEcCtD
Glyburide—Hypersensitivity—Bleomycin—skin cancer	0.00025	0.002	CcSEcCtD
Glyburide—Decreased appetite—Temozolomide—skin cancer	0.000249	0.00199	CcSEcCtD
Glyburide—Gastrointestinal disorder—Temozolomide—skin cancer	0.000247	0.00198	CcSEcCtD
Glyburide—Hypotension—Fluorouracil—skin cancer	0.000246	0.00198	CcSEcCtD
Glyburide—Asthenia—Bleomycin—skin cancer	0.000243	0.00195	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00024	0.00193	CcSEcCtD
Glyburide—Pruritus—Bleomycin—skin cancer	0.00024	0.00192	CcSEcCtD
Glyburide—Paraesthesia—Fluorouracil—skin cancer	0.000237	0.0019	CcSEcCtD
Glyburide—Alopecia—Docetaxel—skin cancer	0.000237	0.0019	CcSEcCtD
Glyburide—Feeling abnormal—Temozolomide—skin cancer	0.000236	0.00189	CcSEcCtD
Glyburide—Dyspnoea—Fluorouracil—skin cancer	0.000235	0.00188	CcSEcCtD
Glyburide—Gastrointestinal pain—Temozolomide—skin cancer	0.000234	0.00188	CcSEcCtD
Glyburide—Erythema—Docetaxel—skin cancer	0.000233	0.00187	CcSEcCtD
Glyburide—Malnutrition—Docetaxel—skin cancer	0.000233	0.00187	CcSEcCtD
Glyburide—Hypersensitivity—Dactinomycin—skin cancer	0.000233	0.00187	CcSEcCtD
Glyburide—Dyspepsia—Fluorouracil—skin cancer	0.000232	0.00186	CcSEcCtD
Glyburide—SLC15A2—lymph node—skin cancer	0.000231	0.0027	CbGeAlD
Glyburide—ABCA1—Fatty acid, triacylglycerol, and ketone body metabolism—PLIN2—skin cancer	0.000231	0.0225	CbGpPWpGaD
Glyburide—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—PLIN2—skin cancer	0.000231	0.0225	CbGpPWpGaD
Glyburide—Decreased appetite—Fluorouracil—skin cancer	0.000229	0.00184	CcSEcCtD
Glyburide—ABCC1—lymph node—skin cancer	0.000229	0.00267	CbGeAlD
Glyburide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000228	0.00183	CcSEcCtD
Glyburide—Urticaria—Temozolomide—skin cancer	0.000227	0.00182	CcSEcCtD
Glyburide—Asthenia—Dactinomycin—skin cancer	0.000227	0.00182	CcSEcCtD
Glyburide—Abdominal pain—Temozolomide—skin cancer	0.000226	0.00181	CcSEcCtD
Glyburide—CYP3A4—female reproductive system—skin cancer	0.000225	0.00263	CbGeAlD
Glyburide—Feeling abnormal—Fluorouracil—skin cancer	0.000217	0.00174	CcSEcCtD
Glyburide—Diarrhoea—Dactinomycin—skin cancer	0.000216	0.00174	CcSEcCtD
Glyburide—Vomiting—Bleomycin—skin cancer	0.000216	0.00173	CcSEcCtD
Glyburide—Anaemia—Docetaxel—skin cancer	0.000216	0.00173	CcSEcCtD
Glyburide—ABCB1—epithelium—skin cancer	0.000215	0.00251	CbGeAlD
Glyburide—Rash—Bleomycin—skin cancer	0.000214	0.00171	CcSEcCtD
Glyburide—Dermatitis—Bleomycin—skin cancer	0.000214	0.00171	CcSEcCtD
Glyburide—Hypersensitivity—Temozolomide—skin cancer	0.000211	0.00169	CcSEcCtD
Glyburide—Urticaria—Fluorouracil—skin cancer	0.000209	0.00168	CcSEcCtD
Glyburide—Leukopenia—Docetaxel—skin cancer	0.000209	0.00167	CcSEcCtD
Glyburide—Asthenia—Temozolomide—skin cancer	0.000205	0.00165	CcSEcCtD
Glyburide—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.000203	0.0198	CbGpPWpGaD
Glyburide—Pruritus—Temozolomide—skin cancer	0.000202	0.00162	CcSEcCtD
Glyburide—Convulsion—Docetaxel—skin cancer	0.000202	0.00162	CcSEcCtD
Glyburide—Nausea—Bleomycin—skin cancer	0.000202	0.00162	CcSEcCtD
Glyburide—Vomiting—Dactinomycin—skin cancer	0.000201	0.00161	CcSEcCtD
Glyburide—CPT1A—Circadian rythm related genes—NKX2-1—skin cancer	0.000201	0.0195	CbGpPWpGaD
Glyburide—Rash—Dactinomycin—skin cancer	0.000199	0.0016	CcSEcCtD
Glyburide—Arthralgia—Docetaxel—skin cancer	0.000199	0.00159	CcSEcCtD
Glyburide—Myalgia—Docetaxel—skin cancer	0.000199	0.00159	CcSEcCtD
Glyburide—Diarrhoea—Temozolomide—skin cancer	0.000196	0.00157	CcSEcCtD
Glyburide—Hypersensitivity—Fluorouracil—skin cancer	0.000194	0.00156	CcSEcCtD
Glyburide—Confusional state—Docetaxel—skin cancer	0.000192	0.00154	CcSEcCtD
Glyburide—Oedema—Docetaxel—skin cancer	0.00019	0.00153	CcSEcCtD
Glyburide—ABCG2—lymph node—skin cancer	0.000189	0.00221	CbGeAlD
Glyburide—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.000189	0.0184	CbGpPWpGaD
Glyburide—Nausea—Dactinomycin—skin cancer	0.000188	0.00151	CcSEcCtD
Glyburide—Shock—Docetaxel—skin cancer	0.000187	0.0015	CcSEcCtD
Glyburide—Nervous system disorder—Docetaxel—skin cancer	0.000187	0.0015	CcSEcCtD
Glyburide—Pruritus—Fluorouracil—skin cancer	0.000187	0.0015	CcSEcCtD
Glyburide—ABCB1—mammalian vulva—skin cancer	0.000186	0.00218	CbGeAlD
Glyburide—Thrombocytopenia—Docetaxel—skin cancer	0.000186	0.00149	CcSEcCtD
Glyburide—Vomiting—Temozolomide—skin cancer	0.000182	0.00146	CcSEcCtD
Glyburide—Anorexia—Docetaxel—skin cancer	0.000181	0.00145	CcSEcCtD
Glyburide—Rash—Temozolomide—skin cancer	0.00018	0.00145	CcSEcCtD
Glyburide—Diarrhoea—Fluorouracil—skin cancer	0.00018	0.00145	CcSEcCtD
Glyburide—Dermatitis—Temozolomide—skin cancer	0.00018	0.00145	CcSEcCtD
Glyburide—Headache—Temozolomide—skin cancer	0.000179	0.00144	CcSEcCtD
Glyburide—Hypotension—Docetaxel—skin cancer	0.000178	0.00143	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000173	0.00139	CcSEcCtD
Glyburide—Paraesthesia—Docetaxel—skin cancer	0.000171	0.00137	CcSEcCtD
Glyburide—Nausea—Temozolomide—skin cancer	0.00017	0.00136	CcSEcCtD
Glyburide—Dyspnoea—Docetaxel—skin cancer	0.00017	0.00136	CcSEcCtD
Glyburide—Vomiting—Fluorouracil—skin cancer	0.000168	0.00134	CcSEcCtD
Glyburide—Dyspepsia—Docetaxel—skin cancer	0.000168	0.00134	CcSEcCtD
Glyburide—ABCG2—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000167	0.0162	CbGpPWpGaD
Glyburide—Rash—Fluorouracil—skin cancer	0.000166	0.00133	CcSEcCtD
Glyburide—Dermatitis—Fluorouracil—skin cancer	0.000166	0.00133	CcSEcCtD
Glyburide—CFTR—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000166	0.0161	CbGpPWpGaD
Glyburide—ABCB1—lymphoid tissue—skin cancer	0.000165	0.00193	CbGeAlD
Glyburide—Decreased appetite—Docetaxel—skin cancer	0.000165	0.00133	CcSEcCtD
Glyburide—Headache—Fluorouracil—skin cancer	0.000165	0.00132	CcSEcCtD
Glyburide—Gastrointestinal disorder—Docetaxel—skin cancer	0.000164	0.00132	CcSEcCtD
Glyburide—ABCB1—female reproductive system—skin cancer	0.00016	0.00186	CbGeAlD
Glyburide—Feeling abnormal—Docetaxel—skin cancer	0.000157	0.00126	CcSEcCtD
Glyburide—Nausea—Fluorouracil—skin cancer	0.000157	0.00126	CcSEcCtD
Glyburide—SLC22A7—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000156	0.0152	CbGpPWpGaD
Glyburide—Gastrointestinal pain—Docetaxel—skin cancer	0.000156	0.00125	CcSEcCtD
Glyburide—Abdominal pain—Docetaxel—skin cancer	0.00015	0.00121	CcSEcCtD
Glyburide—Hypersensitivity—Docetaxel—skin cancer	0.00014	0.00112	CcSEcCtD
Glyburide—Asthenia—Docetaxel—skin cancer	0.000137	0.00109	CcSEcCtD
Glyburide—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000135	0.0131	CbGpPWpGaD
Glyburide—Pruritus—Docetaxel—skin cancer	0.000135	0.00108	CcSEcCtD
Glyburide—ABCC3—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000134	0.013	CbGpPWpGaD
Glyburide—ABCB1—head—skin cancer	0.000133	0.00156	CbGeAlD
Glyburide—Diarrhoea—Docetaxel—skin cancer	0.00013	0.00104	CcSEcCtD
Glyburide—KCNJ5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000122	0.0119	CbGpPWpGaD
Glyburide—Vomiting—Docetaxel—skin cancer	0.000121	0.00097	CcSEcCtD
Glyburide—Rash—Docetaxel—skin cancer	0.00012	0.000962	CcSEcCtD
Glyburide—Dermatitis—Docetaxel—skin cancer	0.00012	0.000961	CcSEcCtD
Glyburide—ABCC9—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00012	0.0116	CbGpPWpGaD
Glyburide—Headache—Docetaxel—skin cancer	0.000119	0.000956	CcSEcCtD
Glyburide—Nausea—Docetaxel—skin cancer	0.000113	0.000906	CcSEcCtD
Glyburide—SLCO2B1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000109	0.0106	CbGpPWpGaD
Glyburide—ABCC1—S1P1 pathway—PTGS2—skin cancer	9.78e-05	0.00951	CbGpPWpGaD
Glyburide—ABCB1—lymph node—skin cancer	9.34e-05	0.00109	CbGeAlD
Glyburide—ABCG2—Fluoropyrimidine Activity—ERCC2—skin cancer	9.23e-05	0.00898	CbGpPWpGaD
Glyburide—CPT1A—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	9.21e-05	0.00896	CbGpPWpGaD
Glyburide—ABCA1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	9.21e-05	0.00896	CbGpPWpGaD
Glyburide—KCNJ5—Transmission across Chemical Synapses—BRAF—skin cancer	9.17e-05	0.00891	CbGpPWpGaD
Glyburide—SLC15A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	9.09e-05	0.00884	CbGpPWpGaD
Glyburide—ABCB1—HIF-1-alpha transcription factor network—PLIN2—skin cancer	9.01e-05	0.00876	CbGpPWpGaD
Glyburide—SLC22A7—SLC-mediated transmembrane transport—SLC12A2—skin cancer	8.92e-05	0.00868	CbGpPWpGaD
Glyburide—SLC15A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	8.43e-05	0.0082	CbGpPWpGaD
Glyburide—ABCA1—Selenium Micronutrient Network—PTGS2—skin cancer	7.82e-05	0.00761	CbGpPWpGaD
Glyburide—KCNJ5—Neuronal System—BRAF—skin cancer	7.02e-05	0.00683	CbGpPWpGaD
Glyburide—SLCO1A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	6.66e-05	0.00648	CbGpPWpGaD
Glyburide—ABCA1—Vitamin B12 Metabolism—IL6—skin cancer	6.59e-05	0.00641	CbGpPWpGaD
Glyburide—SLC22A6—SLC-mediated transmembrane transport—SLC12A2—skin cancer	6.26e-05	0.00609	CbGpPWpGaD
Glyburide—ABCA1—Folate Metabolism—TP53—skin cancer	5.86e-05	0.0057	CbGpPWpGaD
Glyburide—CPT1A—AMPK Signaling—TP53—skin cancer	5.66e-05	0.0055	CbGpPWpGaD
Glyburide—CPT1A—Circadian rythm related genes—CDK4—skin cancer	5.65e-05	0.0055	CbGpPWpGaD
Glyburide—KCNJ5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	5.61e-05	0.00545	CbGpPWpGaD
Glyburide—SLC22A7—Fluoropyrimidine Activity—TP53—skin cancer	5.58e-05	0.00542	CbGpPWpGaD
Glyburide—ABCC9—Neuronal System—BRAF—skin cancer	5.55e-05	0.0054	CbGpPWpGaD
Glyburide—SLCO2B1—Transmembrane transport of small molecules—SLC12A2—skin cancer	5.52e-05	0.00536	CbGpPWpGaD
Glyburide—ABCA1—Folate Metabolism—IL6—skin cancer	5.37e-05	0.00522	CbGpPWpGaD
Glyburide—ABCC8—Transmembrane transport of small molecules—SLC12A2—skin cancer	5.13e-05	0.00499	CbGpPWpGaD
Glyburide—ABCG2—HIF-1-alpha transcription factor network—TERT—skin cancer	4.97e-05	0.00483	CbGpPWpGaD
Glyburide—ABCC3—Fluoropyrimidine Activity—TP53—skin cancer	4.78e-05	0.00465	CbGpPWpGaD
Glyburide—KCNJ1—Neuronal System—BRAF—skin cancer	4.65e-05	0.00452	CbGpPWpGaD
Glyburide—SLC15A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	4.62e-05	0.00449	CbGpPWpGaD
Glyburide—SLC22A7—Transmembrane transport of small molecules—SLC12A2—skin cancer	4.54e-05	0.00441	CbGpPWpGaD
Glyburide—ABCC1—Arachidonic acid metabolism—PTGS2—skin cancer	4.51e-05	0.00439	CbGpPWpGaD
Glyburide—ABCB11—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	4.5e-05	0.00437	CbGpPWpGaD
Glyburide—ABCC3—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	4.31e-05	0.00419	CbGpPWpGaD
Glyburide—SLC15A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	4.29e-05	0.00417	CbGpPWpGaD
Glyburide—ABCA1—Selenium Micronutrient Network—IL6—skin cancer	4.26e-05	0.00414	CbGpPWpGaD
Glyburide—KCNJ5—Transmission across Chemical Synapses—HRAS—skin cancer	4.21e-05	0.0041	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—PLIN2—skin cancer	4.1e-05	0.00399	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—PLIN2—skin cancer	4.1e-05	0.00399	CbGpPWpGaD
Glyburide—ABCC3—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.89e-05	0.00378	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	3.75e-05	0.00365	CbGpPWpGaD
Glyburide—SLCO1A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.38e-05	0.00329	CbGpPWpGaD
Glyburide—ABCC1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	3.38e-05	0.00329	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—CSPG4—skin cancer	3.31e-05	0.00321	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—CSPG4—skin cancer	3.31e-05	0.00321	CbGpPWpGaD
Glyburide—ABCG2—Fluoropyrimidine Activity—TP53—skin cancer	3.29e-05	0.0032	CbGpPWpGaD
Glyburide—ALB—SLC-mediated transmembrane transport—SLC12A2—skin cancer	3.25e-05	0.00316	CbGpPWpGaD
Glyburide—KCNJ5—Neuronal System—HRAS—skin cancer	3.23e-05	0.00314	CbGpPWpGaD
Glyburide—SLC22A6—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.18e-05	0.00309	CbGpPWpGaD
Glyburide—ABCC2—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.08e-05	0.003	CbGpPWpGaD
Glyburide—ABCC1—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.05e-05	0.00296	CbGpPWpGaD
Glyburide—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—skin cancer	2.9e-05	0.00282	CbGpPWpGaD
Glyburide—CPT1A—SIDS Susceptibility Pathways—IL6—skin cancer	2.7e-05	0.00262	CbGpPWpGaD
Glyburide—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	2.69e-05	0.00261	CbGpPWpGaD
Glyburide—ABCG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	2.68e-05	0.00261	CbGpPWpGaD
Glyburide—ABCC9—Neuronal System—HRAS—skin cancer	2.55e-05	0.00248	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—PLIN2—skin cancer	2.53e-05	0.00246	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—PLIN2—skin cancer	2.46e-05	0.00239	CbGpPWpGaD
Glyburide—CPT1A—Circadian rythm related genes—TP53—skin cancer	2.4e-05	0.00234	CbGpPWpGaD
Glyburide—ABCC8—Neuronal System—BRAF—skin cancer	2.38e-05	0.00231	CbGpPWpGaD
Glyburide—KCNJ11—Neuronal System—BRAF—skin cancer	2.31e-05	0.00224	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—ENO2—skin cancer	2.25e-05	0.00219	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—ENO2—skin cancer	2.25e-05	0.00219	CbGpPWpGaD
Glyburide—CPT1A—Circadian rythm related genes—IL6—skin cancer	2.2e-05	0.00214	CbGpPWpGaD
Glyburide—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	2.2e-05	0.00214	CbGpPWpGaD
Glyburide—KCNJ1—Neuronal System—HRAS—skin cancer	2.14e-05	0.00208	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	2.11e-05	0.00205	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—CSPG4—skin cancer	2.04e-05	0.00199	CbGpPWpGaD
Glyburide—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	2.01e-05	0.00195	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—PLIN2—skin cancer	2e-05	0.00195	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	2e-05	0.00194	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—CSPG4—skin cancer	1.98e-05	0.00193	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—PLIN2—skin cancer	1.92e-05	0.00187	CbGpPWpGaD
Glyburide—ALB—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.83e-05	0.00178	CbGpPWpGaD
Glyburide—ABCA1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.76e-05	0.00171	CbGpPWpGaD
Glyburide—CPT1A—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.76e-05	0.00171	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—PLIN2—skin cancer	1.67e-05	0.00163	CbGpPWpGaD
Glyburide—ALB—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.65e-05	0.00161	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.65e-05	0.0016	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—CSPG4—skin cancer	1.61e-05	0.00157	CbGpPWpGaD
Glyburide—ALB—Selenium Micronutrient Network—PTGS2—skin cancer	1.56e-05	0.00152	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—CSPG4—skin cancer	1.55e-05	0.00151	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—PLIN2—skin cancer	1.5e-05	0.00146	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.5e-05	0.00146	CbGpPWpGaD
Glyburide—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.45e-05	0.00141	CbGpPWpGaD
Glyburide—ABCC1—Disease—CSPG4—skin cancer	1.45e-05	0.00141	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—ENO2—skin cancer	1.39e-05	0.00135	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—CSPG4—skin cancer	1.35e-05	0.00131	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—ENO2—skin cancer	1.35e-05	0.00131	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—PLIN2—skin cancer	1.32e-05	0.00129	CbGpPWpGaD
Glyburide—ALB—Vitamin B12 Metabolism—IL6—skin cancer	1.31e-05	0.00128	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—ERCC2—skin cancer	1.31e-05	0.00127	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—ERCC2—skin cancer	1.31e-05	0.00127	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—CSPG4—skin cancer	1.21e-05	0.00118	CbGpPWpGaD
Glyburide—ALB—Folate Metabolism—TP53—skin cancer	1.17e-05	0.00114	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—ENO2—skin cancer	1.1e-05	0.00107	CbGpPWpGaD
Glyburide—ABCC8—Neuronal System—HRAS—skin cancer	1.09e-05	0.00106	CbGpPWpGaD
Glyburide—ALB—Folate Metabolism—IL6—skin cancer	1.07e-05	0.00104	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—CSPG4—skin cancer	1.07e-05	0.00104	CbGpPWpGaD
Glyburide—KCNJ11—Neuronal System—HRAS—skin cancer	1.06e-05	0.00103	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—ENO2—skin cancer	1.05e-05	0.00102	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.03e-05	0.000999	CbGpPWpGaD
Glyburide—ABCC1—Disease—ENO2—skin cancer	9.84e-06	0.000957	CbGpPWpGaD
Glyburide—ABCC1—Disease—SHH—skin cancer	9.84e-06	0.000957	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—ENO2—skin cancer	9.16e-06	0.000891	CbGpPWpGaD
Glyburide—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.58e-06	0.000835	CbGpPWpGaD
Glyburide—ALB—Selenium Micronutrient Network—IL6—skin cancer	8.49e-06	0.000826	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—ENO2—skin cancer	8.24e-06	0.000802	CbGpPWpGaD
Glyburide—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.23e-06	0.0008	CbGpPWpGaD
Glyburide—ALB—Metabolism—PLIN2—skin cancer	8.17e-06	0.000794	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—ERCC2—skin cancer	8.06e-06	0.000784	CbGpPWpGaD
Glyburide—ABCC1—Disease—FOXO4—skin cancer	8.03e-06	0.00078	CbGpPWpGaD
Glyburide—ABCA1—Metabolism—PTGS2—skin cancer	7.83e-06	0.000761	CbGpPWpGaD
Glyburide—CPT1A—Metabolism—PTGS2—skin cancer	7.83e-06	0.000761	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—ERCC2—skin cancer	7.82e-06	0.00076	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	7.35e-06	0.000714	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—PLIN2—skin cancer	7.33e-06	0.000713	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—ENO2—skin cancer	7.25e-06	0.000705	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.17e-06	0.000697	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—PLIN2—skin cancer	7.16e-06	0.000696	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—PLIN2—skin cancer	6.69e-06	0.00065	CbGpPWpGaD
Glyburide—ALB—Metabolism—CSPG4—skin cancer	6.59e-06	0.00064	CbGpPWpGaD
Glyburide—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.45e-06	0.000627	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—ERCC2—skin cancer	6.37e-06	0.00062	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—ERCC2—skin cancer	6.11e-06	0.000594	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—CSPG4—skin cancer	5.91e-06	0.000575	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—CSPG4—skin cancer	5.77e-06	0.000561	CbGpPWpGaD
Glyburide—ABCC1—Disease—ERCC2—skin cancer	5.72e-06	0.000556	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—CSPG4—skin cancer	5.39e-06	0.000524	CbGpPWpGaD
Glyburide—ABCC1—Disease—TERT—skin cancer	5.36e-06	0.000521	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—ERCC2—skin cancer	5.32e-06	0.000517	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	4.92e-06	0.000478	CbGpPWpGaD
Glyburide—ABCC8—Metabolism—PTGS2—skin cancer	4.84e-06	0.00047	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—ERCC2—skin cancer	4.79e-06	0.000466	CbGpPWpGaD
Glyburide—KCNJ11—Metabolism—PTGS2—skin cancer	4.69e-06	0.000456	CbGpPWpGaD
Glyburide—ALB—Metabolism—ENO2—skin cancer	4.48e-06	0.000435	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—PLIN2—skin cancer	4.41e-06	0.000429	CbGpPWpGaD
Glyburide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	4.37e-06	0.000425	CbGpPWpGaD
Glyburide—ABCC1—Disease—BRAF—skin cancer	4.24e-06	0.000413	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—ERCC2—skin cancer	4.21e-06	0.00041	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—ENO2—skin cancer	4.02e-06	0.000391	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—ENO2—skin cancer	3.92e-06	0.000381	CbGpPWpGaD
Glyburide—ABCB11—Metabolism—PTGS2—skin cancer	3.82e-06	0.000372	CbGpPWpGaD
Glyburide—ABCC3—Metabolism—PTGS2—skin cancer	3.66e-06	0.000356	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—ENO2—skin cancer	3.66e-06	0.000356	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—CSPG4—skin cancer	3.55e-06	0.000346	CbGpPWpGaD
Glyburide—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.5e-06	0.00034	CbGpPWpGaD
Glyburide—ABCC1—Disease—PTGS2—skin cancer	3.43e-06	0.000333	CbGpPWpGaD
Glyburide—SLCO1A2—Metabolism—PTGS2—skin cancer	3.19e-06	0.00031	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.14e-06	0.000306	CbGpPWpGaD
Glyburide—ALB—Hemostasis—NRAS—skin cancer	2.99e-06	0.000291	CbGpPWpGaD
Glyburide—ABCC1—Metabolism—PTGS2—skin cancer	2.87e-06	0.000279	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.87e-06	0.000279	CbGpPWpGaD
Glyburide—ABCC1—Disease—NRAS—skin cancer	2.67e-06	0.000259	CbGpPWpGaD
Glyburide—ALB—Metabolism—ERCC2—skin cancer	2.6e-06	0.000253	CbGpPWpGaD
Glyburide—ALB—Hemostasis—KRAS—skin cancer	2.58e-06	0.00025	CbGpPWpGaD
Glyburide—ABCG2—Metabolism—PTGS2—skin cancer	2.53e-06	0.000246	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—ENO2—skin cancer	2.42e-06	0.000235	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—ERCC2—skin cancer	2.33e-06	0.000227	CbGpPWpGaD
Glyburide—ABCC1—Disease—KRAS—skin cancer	2.3e-06	0.000223	CbGpPWpGaD
Glyburide—ALB—Hemostasis—TP53—skin cancer	2.29e-06	0.000223	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—ERCC2—skin cancer	2.28e-06	0.000222	CbGpPWpGaD
Glyburide—ALB—Hemostasis—HRAS—skin cancer	2.19e-06	0.000213	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—ERCC2—skin cancer	2.13e-06	0.000207	CbGpPWpGaD
Glyburide—ABCC1—Disease—HRAS—skin cancer	1.95e-06	0.00019	CbGpPWpGaD
Glyburide—ABCC1—Disease—IL6—skin cancer	1.87e-06	0.000182	CbGpPWpGaD
Glyburide—ALB—Metabolism—PTGS2—skin cancer	1.56e-06	0.000152	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—ERCC2—skin cancer	1.4e-06	0.000136	CbGpPWpGaD
Glyburide—CYP2C19—Metabolism—PTGS2—skin cancer	1.4e-06	0.000136	CbGpPWpGaD
Glyburide—ABCB1—Metabolism—PTGS2—skin cancer	1.37e-06	0.000133	CbGpPWpGaD
Glyburide—CYP2C9—Metabolism—PTGS2—skin cancer	1.28e-06	0.000124	CbGpPWpGaD
Glyburide—CYP3A4—Metabolism—PTGS2—skin cancer	8.42e-07	8.18e-05	CbGpPWpGaD
